Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEONASDAQ:CALTNASDAQ:OCULNASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.42-2.4%$5.29$3.93▼$7.32$328.43M1.68619,543 shs957,198 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AOCULOcular Therapeutix$7.30+1.1%$7.36$4.79▼$11.78$1.16B1.511.40 million shs1.63 million shsPCRXPacira BioSciences$25.75-1.2%$25.21$11.16▼$31.64$1.19B0.56972,523 shs477,629 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-2.43%+5.25%+22.99%+11.07%+49.65%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+84.25%OCULOcular Therapeutix+1.11%+1.11%-7.04%+4.29%+21.67%PCRXPacira BioSciences-1.23%-0.43%+2.18%+2.34%-16.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.751 of 5 stars3.51.00.04.53.02.50.0CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AOCULOcular Therapeutix4.1996 of 5 stars3.43.00.04.14.22.50.0PCRXPacira BioSciences1.9767 of 5 stars1.21.00.03.92.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 3.00Buy$18.50188.16% UpsideCALTCalliditas Therapeutics AB (publ) 2.00Hold$39.25-1.88% DownsideOCULOcular Therapeutix 2.88Moderate Buy$16.25122.60% UpsidePCRXPacira BioSciences 2.33Hold$26.442.70% UpsideCurrent Analyst Ratings BreakdownLatest ABEO, PCRX, OCUL, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ABEOAbeona TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $20.005/15/2025ABEOAbeona TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/9/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $30.005/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/30/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.004/8/2025OCULOcular TherapeutixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/8/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/8/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/8/2025PCRXPacira BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $65.003/24/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/18/2025OCULOcular TherapeutixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$17.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M93.84N/AN/A$0.60 per share10.70CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74OCULOcular Therapeutix$59.65M19.50N/AN/A$0.79 per share9.24PCRXPacira BioSciences$702.77M1.70$3.96 per share6.50$18.74 per share1.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$1.27N/AN/AN/AN/A-203.27%-64.56%8/11/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AOCULOcular Therapeutix-$80.74M-$1.15N/AN/AN/A-283.74%-45.18%-30.87%8/6/2025 (Estimated)PCRXPacira BioSciences$41.96M-$2.28N/A10.02N/A-13.07%13.42%7.19%7/29/2025 (Estimated)Latest ABEO, PCRX, OCUL, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ABEOAbeona Therapeutics-$0.35-$0.24+$0.11-$0.24N/AN/A3/20/2025Q4 2024ABEOAbeona Therapeutics-$0.43-$0.24+$0.19-$0.14$0.10 millionN/A3/3/2025Q4 2024OCULOcular Therapeutix-$0.24-$0.29-$0.05-$0.29$16.89 million$17.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.316.126.12CALTCalliditas Therapeutics AB (publ)9.442.692.59OCULOcular Therapeutix0.1913.0112.94PCRXPacira BioSciences0.512.251.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%CALTCalliditas Therapeutics AB (publ)2.83%OCULOcular Therapeutix59.21%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%CALTCalliditas Therapeutics AB (publ)2.20%OCULOcular Therapeutix2.30%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A51.16 million41.12 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableOCULOcular Therapeutix230159.30 million151.71 millionOptionablePCRXPacira BioSciences72046.29 million43.22 millionOptionableABEO, PCRX, OCUL, and CALT HeadlinesRecent News About These CompaniesPacira at RBC Conference: Strategic Growth and Gene Therapy FocusMay 23 at 5:29 AM | uk.investing.comPacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%May 22 at 10:46 AM | finance.yahoo.comGraham Capital Management L.P. Sells 61,645 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)May 21 at 4:05 AM | marketbeat.com1,075,673 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Purchased by Point72 Asset Management L.P.May 20, 2025 | marketbeat.comGotham Asset Management LLC Cuts Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)May 20, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Comerica BankMay 19, 2025 | marketbeat.comNorthern Trust Corp Buys 145,205 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)May 19, 2025 | marketbeat.comNumerai GP LLC Buys Shares of 15,724 Pacira BioSciences, Inc. (NASDAQ:PCRX)May 18, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 173,956 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)May 17, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Takes $8.56 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)May 16, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Voya Investment Management LLCMay 15, 2025 | marketbeat.comRaymond James Financial Inc. Invests $190,000 in Pacira BioSciences, Inc. (NASDAQ:PCRX)May 15, 2025 | marketbeat.comPacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesMay 14, 2025 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Algert Global LLCMay 13, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Cubist Systematic Strategies LLCMay 12, 2025 | marketbeat.comBokf Na Buys New Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)May 12, 2025 | marketbeat.comBalyasny Asset Management L.P. Makes New Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)May 12, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Given New $30.00 Price Target at Needham & Company LLCMay 11, 2025 | marketbeat.comTruist Financial Sticks to Its Hold Rating for Pacira Pharmaceuticals (PCRX)May 11, 2025 | theglobeandmail.com33,813 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Bought by Brevan Howard Capital Management LPMay 11, 2025 | marketbeat.comAxa S.A. Buys Shares of 89,482 Pacira BioSciences, Inc. (NASDAQ:PCRX)May 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABEO, PCRX, OCUL, and CALT Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$6.42 -0.16 (-2.43%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.46 +0.04 (+0.55%) As of 05/23/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 05/22/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Ocular Therapeutix NASDAQ:OCUL$7.30 +0.08 (+1.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.14 -0.16 (-2.18%) As of 05/23/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Pacira BioSciences NASDAQ:PCRX$25.75 -0.32 (-1.23%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$25.77 +0.02 (+0.08%) As of 05/23/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
